KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Debt to Equity: 2020-2025

Historic Debt to Equity for Regeneron Pharmaceuticals (REGN) over the last 6 years, with Sep 2025 value amounting to $0.06.

  • Regeneron Pharmaceuticals' Debt to Equity fell 5.18% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.06, marking a year-over-year decrease of 5.18%. This contributed to the annual value of $0.07 for FY2024, which is 11.45% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Debt to Equity of $0.06 as of Q3 2025, which was down 3.25% from $0.07 recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Debt to Equity peaked at $0.17 during Q1 2021, and registered a low of $0.06 during Q3 2025.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Debt to Equity value was $0.07 (recorded in 2024), while the average stood at $0.07.
  • Data for Regeneron Pharmaceuticals' Debt to Equity shows a maximum YoY crashed of 41.29% (in 2021) over the last 5 years.
  • Regeneron Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.11 in 2021, then decreased by 17.13% to $0.09 in 2022, then fell by 12.67% to $0.08 in 2023, then decreased by 11.45% to $0.07 in 2024, then declined by 5.18% to $0.06 in 2025.
  • Its last three reported values are $0.06 in Q3 2025, $0.07 for Q2 2025, and $0.07 during Q1 2025.